Background: Congenital heart defects (CHD) are the most common type of birth defect, affecting approximately 8 in 1,000 newborns. Hundreds of genes have been reported as CHD candidate genes. Nevertheless, each patient/patient group may demonstrate unique etiologic characteristics requiring personalized treatment.
INTRODUCTION
Congenital heart defects (CHD) are heart and large blood vessel anatomical abnormalities occurring during embryonic development [1] . CHD can result from genetic factors, or environmental factors; however, a combination of both is typical [2, 3] . Recently, there have been an increased number of articles reporting hundreds of genes/proteins related to CHD, many of which were suggested as candidate genes for the disease However, every patient/patient group has unique human genome variations that requires treatment based on their predicted response or risk of disease [4] . Sparse representation has recently received significant attention in applications such as signal recovery and significant components identification [5, 6] . However, in the cases of large variable and small sample number applications, specific modulation is required to fulfil the variable selected task. In many biomedical problems (e.g., genomic data, image data) samples are far outnumbered by variables.
This study proposes a sparse representationbased variable selection (SRVS) algorithm for selecting significant biomarkers at different detection resolutions, which has previously been effective in selecting variables from SNP data and fMARI data [7] . Instead of selecting a specific of number of variables, this data-driven method ranks all variables by generating a sparse regression weight for each of them [7] .
MATERIALS AND METHODS
In this section, the proposed SRVS algorithm (Section 2.1) is described and then applied to a CHD candidate genetic biomarker selection problem (Section 2.2). Finally SRVS-selected variables are studied in terms of pathway enrichment analysis (PEA), sub-network enrichment analysis (SNEA), and network connectivity analysis (NCA) (Section 2.3).
SRVS algorithm
In general, a sparse representation model can be presented as Eq. (1).
where y ∈ R n × 1 is the observation vector; x ∈ R n × p are the data measurements and p ≥ n . ε ∈ R n × 1 is the noise-caused measurement error. The goal is to reconstruct the unknown vector δ ∈ R p × 1 based on y and x.
To best approximate y by choosing a small number of non-zeros entries of δ for the model given by Eq. (1), we consider the following L p minimization problem (P0):
where ||*|| p is the L p norm, and p ∈ [0, 1]. The following algorithm is designed to solve the minimization problem (P0) given by Eq. (2) and detect the columns of x relevant to y.
SRVS Algorithm:
1. Initial δ (0) = 0;
2. For the Step ι, randomly choose k columns from x = {x1, ..., xp} to construct a n ⅹ k sub-matrix denoted as x ι ∈ R n × k ; and mark the selected columns' indexes as I ι ∈ R 1 × k ;
3. Solve the following L p minimization problem to find the optimal sparse solution δ ι ∈ R k × 1 :
4. Update δ (ι) with δ ι : δ (ι) (Iι) = δ (ι-1) (Iι) + δ ι ; where δ (ι) (Iι) and δ (ι-1) (Iι) denote the I ι th entries in δ (ι) and δ (ι-1) respectively;
where is a predefined constant, update ι = ι+1, and go to Step 2. Otherwise, set δ = δ (ι) / ι . The non-zero entries in δ correspond to the column vectors selected.
In
Step 3, there are many proposed methods for solving the Lp minimization problem, such as the Homotopy method [8] for p = 1, and the orthogonal matching pursuit (OMP) algorithm [9] for p = 0.
CHD Candidate Genes for Evaluation
A 167-CHD-candidate gene pool was acquired from the CHD-Gene relation data, which was also included in a gene expression data set (GEO: GSE34457 
Validation of the SRVS method
To test the validity of the proposed method, we studied the SRVS selected genes through four approaches: CHD predication, PEA, SNEA and NCA. For comparison purposes, we also compared the performance of the top frequently referenced CHD candidate genes.
Defi nition of two scores
The reference number underlying a gene-disease relationship is defi ned as the gene's reference score (Rscore). The SRVS approach generated weights for each gene is defi ned as the SRVS score (Sscore).
Validation using disease prediction
We hypothesize that significant CHD candidate genes/gene set should contribute to distinguishing CHD patients from healthy controls. A Euclidean, distance-based, multivariate classification [7] of the gene expression data set (GEO: GSE34457), followed by a leave-one-out (LOO) cross-validation, using the overall gene set and the sub-sets selected by Sscore and Rscore as tentative markers, was performed to validate selected gene effectiveness and the proposed SRVS approach. Next a 5,000 run permutation was conducted to test the hypothesis that a randomly-selected gene set of the same size can reach an equal, or higher, classifi cation accuracy (CR).
Enrichment and connectivity analysis
To better understand the underlying functional profi le of the genes selected by Sscore and Rscore, we also conducted a PEA and an SNEA on the top genes selected by the two scores. An NCA was also conducted on the gene subsets using Pathway Studio, to identify connectivity between given genes/ proteins. The weight of an edge is the number of scientific references underlying a reported genegene interaction.
RESULTS

CHD candidate genes for validation
An analysis of CHD-Gene relation data revealed a CHD gene pool of 684 genes, supported by 3,237 articles (Supplementary Table S1 ). Of these 684 CHD candidate genes, 167 were evaluated using the proposed SRVS algorithm with an independent gene expression data (GEO: GSE34457). Fig. 1 
Validation in CHD prediction
The effectiveness of the SRVS-generated metrics, the Sscore, was evaluated using a case/control classification and a LOO cross-validation on an RNA microarray dataset (GEO: GSE34457). This was followed by a 5,000 run permutation test. The Rscore was tested for comparison purposes.
In the LOO cross validation, the 167 genes were ranked by different metric scores, and then the top n (n = 1, 2, …) genes were used as input variables for classification and LOO cross-validation. Fig. 2 presents the results with maximum classification ratios (CRs) marked at the position of corresponding number of genes. Fig. 2 suggests that the top genes using both the Sscore and the Rscore leads to significant better classification accuracies as compared to CRs generated by randomly selected gene sets of same size. Moreover, the highest CRs were acquired by using only the top genes selected by different scores, (See Fig. 2 and Table 1 ). Adding more genes with lower scores do not help to get a better CR, suggesting the validity of both Sscore and Rscore.
To note, the Sscore led to much higher CRs with lower permutation p-values, demonstrating the proposed method's effectiveness. The top 24 Sscore are in Table 2 . The top 24 Rscore genes are provided for comparison purposes. The full lists are in Supplementary Table S2 . 
Compare Top Genes by Sscore and Rscore
To better understand the profile of the genes selected by SRVS approach, the two groups of top genes selected by Sscore and Rscore (Table 2) were compared using PEA and NCA approaches. A twogene overlap: BCOR and G6PC3 (Fig. 3 (a) ) was identifi ed.
Nevertheless, a strong relation between the two gene groups is suggested by an NCA analysis, which detected 94 relations between 18/24 Sscore genes and 18/24 Rscore genes ( Fig. 3 (b) ), supported by more than 3,000 references (Supplementary Table  S3 ). 
Enrichment Analysis
PEA and SNEA results for the different groups listed in Table 3 are presented in this section. At the same enrichment p-value threshold (< 0.001), 152 pathways are enriched by the top 24 Rscoree genes, while only 17 enriched pathways for the Sscore group were identifi ed. The top 10 pathways/ gene sets, by different scores, appear in Table 3 . Complete results are in Supplementary Table S4a and S4b. Table 3 shows that top Sscores genes and those with the top Rscores genese were enriched in different groups of pathways (only one overlap: GOID 0007511), with different p-values (Sscore group: 8.54 E-04 -8.93 E-05; Rscore group: 1.36E-07 -3.01E-12), indicating that the top genes selected by SRVS were functionally different from the most frequently reported ones.
The 17 pathways/gene sets enriched with the 24 Sscore genes (p-value < 0.00091, with 16/24 unique genes; Supplementary Table 4a), held 1 gene set related to heart development (GO: 0007511; p-value = 0.00014, overlap: 4). These sets also held 2 gene sets related to transcription factors for positive DNAtemplated transcription regulation (GO: 0045941; p-value = 0.0006, overlap: 5) and positive regulation of transcription on the RNA polymerase II promoter (GO: 0010552; p-value = 0.00091, overlap: 6). Both have been previously implicated with CHD (Clark et al. 2016 ).
In addition to PEA, a SNEA using Pathway Studio for identifying a selected gene's pathogenic significance to other disorders, possibly related to CHD, was performed. Full results appear in Supplementary Table S5a and S5b. Table4 shows the top 10 disease-related sub-networks enriched by the two gene groups. Table 4 indicates that both groups enriched some other heart defect related sub-networks, as well as other congenital and genetic mutation related sub-networks. Two sub-networks were observed for both groups: congenital malformation and leukemia. 
Connectivity Analysis
In addition to PEA and SNEA, an NCA was performed on the top 24 genes having the highest Rscores and Sscores (Table 2) to generate functional networks. In the Sscore group, 11 of the 24 genes presented 14 direct connections supported with 53 (Fig. 4 (b) ). This observation is consistent with the PEA and SNEA. It suggests that the highest Sscores genes were less functionally related to each other than the Rscore group genes were. 
DISCUSSION AND CONCLUSION
Identification of significant biomarkers based on a small number of observations is a fundamental problem in signal processing. This study proposed a sparse representation based genetic marker selection approach, and applied it to evaluate 167 CHD candidate genes. The genes were identified from a CHD-Gene network relation data set acquired from the ResNet database. This set overlapped with a RNA gene expression data set (GEO: GSE34457). Two metric scores were generated and compared: the Sscore from SRVS analysis, and the Rscore from the CHD-Gene relation data set analysis.
LOO cross validation demonstrated that if whole 167 CHD candidate genes were used, a classifi cation ratio of only 58.14 % was obtained with a permutation p-value of 0.30 (Table 1) . Using both Sscore, and Rscore, top genes resulted in greater CRs (81.40 % and 69.77 %) with a more signifi cant permutation p-value (< 0.017). This suggests a need for variable selection for the candidate CHD genes tested, as well as the efficacy of both Sscore and Rscore.
The top 24 Sscore genes led to the greatest CR with the lowest permutation p-value, demonstrating the effectiveness of the proposed SRVS method in CHD variable selection. The top 24 Rscoreselected genes and the 24 genes selected by SRVS were compared to provide a clearer understanding. Analysis showed that these two groups share only two genes: BCOR and G6PC3 (Fig. 3 (a) ). Enriched pathways (Table 4) , associated sub -networks (Table  5) , and gene-gene interactions (Fig. 4) revealed other differences. The results highlight that even though well-studied CHD candidate genes were significant to the disease and were also effective in disease prediction (LOO permutation p-value = 0.017), they were not the best genetic markers for the subjects involved with the expression data tested (GEO: GSE34457).
Despite differences between the top genes selected by Sscore and Rscore, many of Sscore e n r i c h m e n t p a t h w a y s p r e v i o u s l y r e p o r t e d to associate with CHD were identified. For example, heart development, positive regulation of transcription from the RNA polymerase II promoter, the DNA-templated positive regulation of transcription, the canonical Wnt signaling pathway, and histone deacetylase binding [11] [12] [13] . Furthermore, these genes were also identified to be the genetic basis of other CHD related diseases, such as congenital malformation, cardiac hypertrophy, dystrophy, and cancer [14, 15] . These results support the biological validity of the top genes selected by the SRVS approach.
There is direct literature support for associating CHD and the top 24 genes selected by Sscore (Supplementary Table S1 ). A strong functional association between the top genes selected by the Sscore and Rscore groups (Fig. 3 (b) ) is supported by over 3,000 references (Supplementary Table S3) . Genes with a high Rscore suggests strong support in the literature for linking it to CHD. Our observations provide indirect support for the proposition that the majority of the top genes selected by the SRVS method are functionally signifi cant in CHD.
This study does have several limitations calling for future work. Although the algorithm was tested on 167 CHD candidate genes, there are other genes linked to CHD that were not included in the data set and were, therefore, not analyzed. More inclusive data sets including all CHD genes should be used to test this method's accuracy. The method should also be tested on other diseases to determine its validity.
We conclude that CHD is a complex disease with genetic causes linked to a network composed of a large gene group. Each patient/patient group may present with unique genomic variations requiring treatment based on their particular disease risk prediction, where the proposed SRVS method can be employed effectively.
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